These results suggested that doxorubicin combined with factors released by doxorubicin-treated osteosarcoma cells activate macrophages, which in turn secret soluble factors to upregulate CD47 expression in tumor cells for inhibition of macrophage phagocytosis. The gene discussed is CD47; the disease is neoplasm.